Mouse Anti-LMTK3 Recombinant Antibody (CBYCL-406) (CBMAB-L0307-YC)

Agnarelli, A., Lauer Betrán, A., Papakyriakou, A., Vella, V., Samuels, M., Papanastasopoulos, P., ... & Giamas, G. (2023). The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor. International Journal of Molecular Sciences, 24(1), 865.

Krishnan, A., Dhamodharan, D., Sundaram, T., Sundaram, V., & Byun, H. S. (2022). Computational discovery of novel human LMTK3 inhibitors by high throughput virtual screening using NCI database. Korean Journal of Chemical Engineering, 39(6), 1368-1374.

Vella, V., Giamas, G., & Ditsiou, A. (2022). Diving into the dark kinome: lessons learned from LMTK3. Cancer Gene Therapy, 29(8-9), 1077-1079.

Wang, C., Yang, M., Gu, X., & Gu, Y. (2021). Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway. Bioengineered, 12(1), 6594-6605.

Ortiz, M. A., Michaels, H., Molina, B., Toenjes, S., Davis, J., Marconi, G. D., ... & Nefzi, A. (2020). Discovery of cyclic guanidine-linked sulfonamides as inhibitors of LMTK3 kinase. Bioorganic & Medicinal Chemistry Letters, 30(9), 127108.

Ditsiou, A., Cilibrasi, C., Simigdala, N., Papakyriakou, A., Milton-Harris, L., Vella, V., ... & Giamas, G. (2020). The structure-function relationship of oncogenic LMTK3. Science Advances, 6(46), eabc3099.

Jiang, T., Lu, X., Yang, F., Wang, M., Yang, H., & Xing, N. (2020). LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway. FEBS Open Bio, 10(10), 2107-2121.

Cairns, J., Ingle, J. N., Kalari, K. R., Shepherd, L. E., Kubo, M., Goetz, M. P., ... & Wang, L. (2019). The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. Breast Cancer Research, 21(1), 1-17.

Klug, L. R., Bannon, A. E., Javidi-Sharifi, N., Town, A., Fleming, W. H., VanSlyke, J. K., ... & Heinrich, M. C. (2019). LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma. Oncogene, 38(8), 1200-1210.

Sarma, H., & Mattaparthi, V. S. K. (2019). Structure-based virtual screening of high-affinity ATP-competitive inhibitors against human lemur tyrosine kinase-3 (LMTK3) domain: a novel therapeutic target for breast cancer. Interdisciplinary Sciences: Computational Life Sciences, 11(3), 527-541.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols